The Cutting Edge of Medical Technology Content, Community & Collaboration
Genzyme on the hunt for new products
Colleagues,
As reported in the Boston Globe...Genzyme Corp. may spend about $600 million this year to acquire products that treat chronic diseases, said chief executive Henri Termeer.
Genzyme, the world's largest maker of drugs for rare genetic disorders, will seek opportunities to purchase "personalized drugs, highly specialized medicines where you can easily explain their value," Termeer said yesterday.
Acquisitions made by the Cambridge-based biotechnology company will focus on individual products already tested in humans, Termeer said. He prefers buying products rather than entire companies because he wants to invest in "the value of maintaining the team" that got the new therapies started, he said.
Read on at: http://www.boston.com/business/healthcare/articles/2009/02/24/genzy...
ENJOY!
CC
As reported in the Boston Globe...Genzyme Corp. may spend about $600 million this year to acquire products that treat chronic diseases, said chief executive Henri Termeer.
Genzyme, the world's largest maker of drugs for rare genetic disorders, will seek opportunities to purchase "personalized drugs, highly specialized medicines where you can easily explain their value," Termeer said yesterday.
Acquisitions made by the Cambridge-based biotechnology company will focus on individual products already tested in humans, Termeer said. He prefers buying products rather than entire companies because he wants to invest in "the value of maintaining the team" that got the new therapies started, he said.
Read on at: http://www.boston.com/business/healthcare/articles/2009/02/24/genzy...
ENJOY!
CC
Views: 4
MedTechIQ VideoLibrary
Upcoming Events
© 2024 Created by CC-Conrad Clyburn-MedForeSight.
Powered by
